Dr Elisabeth Whipp, innovative oncologist who spoke out on television against ‘postcode prescribing'
She made headlines in 1997 when she spoke out in an edition of Channel 4's Dispatches against the increasing prevalence of 'postcode prescribing'. She had been treating two breast cancer patients with the drug Taxol; one was from Taunton, and her treatment was funded by the Somerset Health Authority, but the second woman, from Bristol, had to negotiate an overdraft to raise £10,000 to pay for the drugs herself.
'There is always embarrassment about patients having to buy a drug,' Liz Whipp complained. 'After many years in the NHS I'm not used to bargaining with money.' In response, the Avon Health Authority argued that the money was more urgently needed for breast-care nurses.
Liz Whipp was back in the news in early 2003 when it emerged that she had been suspended some weeks earlier amid questions over the experimental radiotherapy she had been prescribing.
Previously, the location of tumour beds had been difficult to pinpoint and radiation had to be directed over the whole breast, with care taken to keep the dose low enough to minimise the risk of damaging the heart. Liz Whipp's innovation had been to use newly developed MRI scanners to locate the tumour beds more precisely and then target higher doses of radiation at a smaller area.
Some of her colleagues considered that she was underestimating the risks that these higher doses posed, and Bristol Royal Infirmary took the decision to investigate her for carrying out treatment that had not been authorised by the National Institute for Health and Care Excellence (Nice). 'If we allow unfettered clinical freedom to take place we will end up with situations where patients will receive treatments which are not in accordance with Nice guidance,' a hospital spokesman insisted.
Liz Whipp suggested in later life, however, that certain male colleagues had not approved of her breaking the omerta around NHS funding and had been waiting for an opportunity to take her down a peg. She was suspected of having broken rules by encouraging patients to complain to their MPs about NHS restrictions on the availability of drugs such as Herceptin.
The suspension of Liz Whipp became a cause célèbre, with the shadow health secretary Liam Fox arguing that she was the victim of an NHS culture that victimised whistleblowers: 'I can't see any case to say this doctor acted in an unprofessional way. In fact, it seems to have been quite the opposite and she has acted in the interest of her patients. Dr Whipp has been suspended for what we regard as totally spurious reasons.'
Her former patients queued up to praise her. One 77-year-old man told the press: 'She is an extremely compassionate woman and very sympathetic. She was the best doctor I could have had and I think that she saved my life.'
Liz Whipp – who pointed out that, of 542 patients given the experimental treatment, only two had seen their cancer return – claimed that she had in fact always followed Nice guidelines. Nevertheless she was suspended for nearly two years while the United Bristol Healthcare NHS Trust investigated her.
She was completely exonerated, but although she returned to work she was deeply pained by the experience and grieved by the thought that many patients had died unnecessarily while her treatment programme was on hold.
The daughter of Brian Whipp, an academic, Elisabeth Clare Whipp was born on September 9 1947. She read medicine at Lady Margaret Hall, Oxford, and worked at the London Hospital and the Royal Free Hospital before moving to Bristol in the early 1980s.
As a long-serving radiotherapy consultant at the Royal Infirmary's Haematology and Oncology Centre, Liz Whipp gained a reputation for speaking her mind. In 1983 she made waves by criticising Prince Charles for visiting the Bristol Cancer Help Centre, a charity that was advocating the rejection of orthodox medicine in favour of alternative treatments: 'I do feel strongly about the Prince of Wales making a Royal tour of something that's full of bogus notions.'
She became renowned for her innovative thinking, which was not confined to the development of radiotherapy. Convinced that the mental welfare of patients played a large role in their recovery, she appointed a clinical psychologist, Dr James Brennan, to work with her at Bristol; this was the first full-time clinical psychology post in cancer services in the NHS.
Experience taught her that when it came to coping with cancer, 'single women… do better, because they tend to have women friends, whereas a lot of married women have husbands they can't talk to about health.'
Described by one friend as 'a statuesque woman, combining a pre-Raphaelite beauty with the charisma of a Valkyrie', Liz Whipp was a keen painter and a fine pianist and singer: on one occasion she found herself in a musical duel with Germaine Greer, competing to see who could give the better rendering of the Queen of the Night's aria from The Magic Flute. She had recently finished the first draft of a gleefully horrific thriller, utilising her medical background to devise a series of especially gruesome murders.
She created a beautiful garden at her home in Clifton, finding room in a relatively small space for a pool of koi carp, a stream, quiet pathways, a grotto and a bamboo grove. Her wide circle of friends was treated to extravagant garden parties complete with fireworks.
On one occasion a neighbour disgruntled by the noise spitefully padlocked the gates at the end of her drive to inconvenience the guests – a futile gesture, as no guest at one of Liz Whipp's parties left until they absolutely had to.
Elisabeth Whipp, born September 9 1947, died April 26 2025
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Turn the looming e-invoicing deadline into a strategic advantage
As part of a broader Digital Transformation Roadmap aimed at reducing paperwork, modernising the UK financial processes, and improving tax compliance, the UK government in May closed a consultation process on whether e-invoicing—currently mandatory only within the NHS—should become standard across all B2B transactions, enabling buyers and sellers to exchange data in a format that is also visible to tax authorities. While the effort to bring more structure and transparency into B2B processes is broadly welcomed by all parties, even the strongest proponents of e-invoicing acknowledge that widespread adoption before 2030 is unlikely. Nevertheless, this is clearly the direction the UK's B2B landscape is heading. Across Europe, e-invoicing has already been the norm since 2020—though its implementation has varied from country to country. This means that any brand operating across Europe is likely already well aware of the challenges involved in transitioning away from paper invoicing—an obstacle many UK organisations have yet to fully confront. The future is digital and integrated I engage with clients across both the EU and the UK and I've observed how organisations on both the buyer and seller sides are either adapting to—or preparing for—the implications of the EU Directive and the UK's recently announced plans. However, when discussing B2B processes, and e-invoicing in particular, it's crucial to understand the process begins much earlier than when the invoice is sent. It starts with onboarding buyers and ensuring full compliance with all relevant regulations. This includes the rules governing the country where your business is officially headquartered, as well as those in any countries where your customers are based. This is especially critical for cross-border transactions, even before considering electronic invoicing. Failing to properly identify the counterparty—known as KYC (Know Your Customer) or KYB (Know Your Buyer)—can result in serious penalties. Compliance is the key lens through which to view the push for e-invoicing. From the EU's perspective, the ultimate goal is to implement robust measures that both prevent fraud and increase transparency in trade. Currently, many sellers still issue paper invoices, which are untraceable and difficult to audit. This means that in most EU countries, there is no automated connection between sellers, buyers, and VAT authorities. As a result, sellers report the VAT they collect, and buyers report the VAT they pay and reclaim—but these records are rarely reconciled at a national level. This mismatch leads to discrepancies, with VAT paid out to buyers often exceeding the amounts declared by sellers. These gaps create opportunities for fraudsters, causing governments to lose an estimated €90 billion annually across the EU as a whole. To address this, the EU is mandating digital invoicing. This means that across all member states, new regulations will require real-time, digital communication between companies and tax authorities. However, it's important to emphasise there is no expectation for each country to implement these requirements in exactly the same way. This approach respects local sovereignty and business practices, but it also means that anyone trading with multiple EU countries must be able to tailor their invoicing to meet each country's specific requirements. As it stands, countries like Italy are already enforcing digital invoicing, requiring sellers to integrate directly with their tax (VAT) systems. Meanwhile, Germany is taking a less stringent approach. Similarly, the Netherlands and Poland are adopting different methods for implementing e-invoicing, with varying policies regarding formats like PDFs and other technical requirements. For buyers or sellers operating in Europe—and soon the UK—these differences don't matter much, as many countries have already announced they will implement digital invoicing in phases. However, since the directive is ultimately enforced on a country-by-country basis, the key takeaway is this: the era of manual, poorly integrated, or hard-to-process invoicing is coming to an end. That's simply the new reality. E-invoicing will boost business In many ways, this shift is a positive development. In some countries, the rules may seem too strict; in others, perhaps too lenient. But once full e-invoicing is implemented, the benefits are likely to extend across the board—from buyers and sellers to citizens and governments. After all, nobody truly benefits from fraud—not governments, legitimate sellers, or genuine buyers—and fraud undermines the integrity of the entire B2B trade ecosystem. Fully transparent digital invoicing will ultimately boost e-commerce and business overall. At its core, B2B trade is about trust: the trust a buyer places in a seller. That trust shapes decisions—whether based on price, quality, or other factors. Simply put, buyers choose sellers they trust. In other words, when a buyer knows exactly what the invoice will look like and how it will be delivered, it adds another layer of clarity. For B2B buyers, having a consistent, predictable invoicing format and a defined delivery channel significantly simplifies the process. This is the kind of level playing field worth striving for. But that doesn't mean the shift to e-invoicing is a simple task—far from it. It's not only sellers who are impacted; buyers now carry legal responsibilities too. In Germany, for instance, buyers are required to accept digital invoices—whether in PDF, email, or Excel format—as a minimum standard. If a buyer demands a paper invoice instead, it breaks the digital chain and puts both parties out of compliance. Not every buyer is ready for this transition—especially those still reliant on traditional paper-based processes. Even among larger, more automated organisations, many have already made significant investments in older technologies like EDI or ERP-based e-invoicing. For those organisations, there's a real risk of sunk costs, as existing systems may require substantial upgrades—or in some cases, those systems may be too outdated to handle the new requirements entirely. The reality is that both the EU and UK e-invoicing regulations are true game-changers for buyers and sellers alike. They require not only technical readiness but also changes to workflows and, more fundamentally, a shift in mindset about how business gets done. It's no surprise that some merchants and suppliers are pushing back. They're facing a significant increase in complexity and administrative burden—which, understandably, can feel overwhelming. Catalyst for digital transformation What happens next will depend on each company's specific circumstances—but in most cases, getting started will require some form of external guidance, particularly from tax or compliance experts. At a recent payments salon in London, one expert made a compelling point: companies should go beyond minimal compliance and consider aligning their e-invoicing strategy with digital payments. Doing so can not only future-proof them against further regulatory changes, but also unlock broader business benefits—such as improved cash flow control. As they put it: 'Yes, you can take a minimal approach to compliance with electronic invoicing, and doing so will bring some benefits, mainly through reducing manual processes. But we encourage companies to view this not just as a compliance task, but as an opportunity to solve broader pain points. When coupled with payments, electronic invoicing unlocks much more value—like helping you manage incoming and outgoing payments with greater efficiency.' They concluded the payoff is well worth the effort: 'Better control over your cash flow, deeper insight into who you're working with, and what kinds of payments are involved—that's where the real benefits of e-invoicing come through.' The shift to e-invoicing across both the EU and UK marks a significant period of change management. Adjustments will be required, and businesses will need to invest time and resources to adapt. But once the systems are in place and widely adopted, the new approach will greatly simplify operations—for both buyers and sellers—and ultimately enhance the entire B2B trade experience. Of course, organisations will need time, resources, expert guidance, and often external IT support to adapt. And by starting preparations now, there's a real opportunity to go beyond basic compliance. Who knows how many other B2B process improvements could be unlocked in parallel? E-invoicing might just be the springboard for broader digital transformation. Inez Berkhof-Hollander is EMEA Vice President for TreviPay "Turn the looming e-invoicing deadline into a strategic advantage" was originally created and published by Electronic Payments International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Medscape
4 hours ago
- Medscape
Early Access to Weight Loss Jabs in NICE Diabetes Plan
People with type 2 diabetes (T2D) in England could be offered earlier access to newer treatments, including weight loss jabs, under draft guidance from the National Institute for Health and Care Excellence (NICE). The guidance, described as the 'biggest shake-up in care for a decade', would see a shift from a one-size-fits-all approach to a focus on personalised treatment to prevent heart failure, heart attacks, and other serious complications. Expanded Use of SGLT-2 Inhibitors The draft guidance recommends expanding access to sodium-glucose co-transporter-2 (SGLT-2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. Currently prescribed as a second-line option, SGLT-2 inhibitors would be available as a joint first-line treatment alongside metformin. They may also be used as monotherapy in patients intolerant to metformin. SGLT-2 inhibitors are once-daily tablets that selectively block the SGLT-2 cotransporter in the proximal renal tubule, responsible for reabsorbing about 90% of filtered glucose. This lowers the renal glucose threshold, increasing urinary glucose excretion and inducing mild osmotic diuresis. However, a 2024 NICE analysis of nearly 590,000 people with T2D in England found under-prescribing of these drugs, particularly among women, older adults, and Black patients. Only 20% of patients with atherosclerotic cardiovascular disease received SGLT-2 inhibitors, with prescribing rates declining in older age groups. NICE estimates that wider use of SGLT-2 inhibitors could save nearly 22,000 lives once uptake reaches 90%. Earlier Access to GLP-1 Agonists The draft guidance also recommends earlier use of glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide or semaglutide. These drugs, previously reserved for later stages of disease, would be considered earlier in treatment for selected groups. NICE further supports wider adoption of digital health tools, including continuous glucose monitoring and community-based digital care. Personalised Treatment Approaches The guidance proposes tailored treatment strategies based on patient characteristics and comorbidities: Adults with cardiovascular disease should receive triple therapy (metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist) Those with early-onset T2D (diagnosed before age 40) should receive dual therapy before considering a GLP-1 receptor agonist Patients with obesity or chronic kidney disease should have specific combinations based on their condition and kidney function, respectively. Adults with clinical frailty should start with metformin monotherapy. Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the draft guidance marks a 'significant evolution' in diabetes care. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes, and other serious complications before they occur,' he said. Burden of Diabetes in the UK Approximately 4.6 million people in the UK have diabetes, with 90% diagnosed with T2D. Diabetes UK estimates that a further 1.3 million may be undiagnosed. The condition costs the NHS £1 million per hour, with 60% of spending linked to complications. Each week, diabetes contributes to more than 930 strokes, 660 heart attacks, and nearly 2990 cases of heart failure. Douglas Twenefour, head of clinical at Diabetes UK, welcomed the draft guidance. 'The majority of people with T2D are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications,' he said. 'Tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease.' Waqaar Shah, a GP partner at Chatfield Health Care in London and chair of the NICE guideline committee, said that these recommendations 'could help reduce health inequalities while providing better outcomes for everyone'. Implementation and Safety The draft guidance remains open for public consultation until 2 October. NICE will review feedback before publishing final recommendations. The guidance aims to promote equitable access to recommended therapies, supported by local training initiatives. Healthcare professionals have also stressed the need for safe prescribing of SGLT-2 inhibitors, which carry risks including diabetic ketoacidosis (DKA). Before starting treatment, providers should assess whether patients have previously experienced DKA, have acute illness, or follow very low-carbohydrate or ketogenic diets.
Business Wire
5 hours ago
- Business Wire
ieso Sharpens Focus on AI-Powered Mental Healthcare with Sale of UK Telecare Services Business
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- ieso, a global leader in evidence-based digital mental health, today announced the sale of its UK telecare services business to Mindler, a leading pan-European digital therapy provider. The acquisition is specific to ieso's NHS-facing care operations in the UK, including delivery of typed and video therapy services. Mindler's press release is available here. "As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we." - Kent Tangen, CEO, ieso Share The parent company, ieso Digital Health Limited, remains fully independent and continues to operate under the ieso brand. With the sale now complete, ieso is entirely focused on scaling its clinical-grade generative AI platform, Velora, to deliver safe, effective, personalized mental health support via SaaS integration into clinical workflows. 'We're proud to have supported thousands of lives through ieso's UK telecare services. That legacy will always be a part of who we are,' said Kent Tangen, CEO at ieso. 'With those operations now in excellent hands at Mindler, ieso is committed to building the future we've long envisioned: delivering safe, effective AI-powered mental healthcare at scale. Our immediate focus is in the US, but our mission is global. As AI adoption accelerates, mental health is emerging as one of its most urgent and natural use cases. The market is moving fast, and so are we.' ieso was advised on the transaction by Cooley LLP and Artis Finance. About ieso ieso is a pioneer in AI-powered mental healthcare, combining clinical expertise with advanced technology to help more people feel better, faster. Its latest product, Velora, is a next-generation generative AI-based program that delivers outcomes on par with human-delivered care and is designed to integrate seamlessly into existing clinical workflows. Backed by over a decade of research and real-world data, ieso is focused on increasing access to safe, effective, and scalable mental health support in the US and beyond. To learn more or request a demo, visit
